Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2073

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 2073
---
 
     13,727,634  
     571,678  
     13,155,956 
  
    Net increase (decrease) in cash and cash equivalents 
    $811,665  
    $(5,218,309) 
    $6,029,974 

107

Net cash used in operating activities

Net cash used in operating activities for the year ended December 31,
2024 primarily reflected a net loss of $8.3 million, adjusted for the reconciliation of non-cash items such as a gain on of the settlement
of vendor liabilities of $3.3 million, depreciation expense of $0.4 million, stock-based compensation of $0.9 million, amortization of
right-of-use asset of $0.7 million and a gain on revaluation of derivative and earnout liabilities of $5.2 million, and changes in operating
asset and liabilities primarily consisting of an increase in prepaid expenses and other current assets of $0.1 million, an increase in
accounts payable of $0.2 million, an increase in accrued liabilities of $2.3 million, and a decrease in operating lease liabilities of
$0.8 million.

Net cash used in operating activities for the year ended December 31,
2023 primarily reflected a net loss of $7.3 million, adjusted for the reconciliation of non-cash items such as depreciation expense of
$0.5 million, stock-based compensation of $0.1 million, amortization of right-of-use asset of $0.7 million and a gain on revaluation of
the preferred stock warrant liability of $0.3 million, and changes in operating asset and liabilities primarily consisting of an increase
in prepaid expenses and other current assets of $0.1 million, an increase in accounts payable of $1.3 million, and a decrease in operating
lease liabilities of $0.7 million.

Net cash provided by financing activities

Net cash provided by financing
activities for the year ended December 31, 2024 amounted to $13.73 million as compared to $0.6 million for the year ended December 31,
2023.

During the year ended December 31, 2024, net cash provided by financing
activities of $13.7 million was primarily attributable to the receipt of net proceeds of $7.2 million from the issuance of Series A and
B Preferred Stock, net proceeds of $0.8 million from the issuance of Series C Preferred